Manager × security

Future Fund LLC HALO holdings history

Who else holds this security? →

HALOZYME THERAPEUTICS INC · CUSIP 40637H109 · CIK 1911970

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Log in to see them.
Citable facts

As of Sep 30, 2026, Future Fund LLC reported 79.80K HALO (shares), valued at $8.81M, or 2.66% of its reported non-derivative portfolio. Filed Nov 13, 2026.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
2.66%
Shares
79.80K
79,799
Reported value
$8.81M
USD

Shares decreased 43.81%; reported value decreased 20.74%, and weight changed -0.53 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q3 20262.66%79,799SEC filing ↗Filed Nov 13, 2026
Q2 20263.19%142,007SEC filing ↗Filed Aug 12, 2026
Q1 20262.16%95,121SEC filing ↗Filed May 6, 2026
Q4 20251.77%83,030SEC filing ↗Filed Feb 10, 2026
Q3 20251.62%62,449SEC filing ↗Filed Nov 12, 2025
Q2 20251.29%55,692SEC filing ↗Filed Aug 7, 2025
Q1 20252.77%33,819SEC filing ↗Filed May 15, 2025
Q4 20242.40%17,596SEC filing ↗Filed Feb 7, 2025
Q3 20241.83%11,096SEC filing ↗Filed Nov 5, 2024
Q2 20244.74%36,295SEC filing ↗Filed Aug 14, 2024
Q1 20244.05%12,275SEC filing ↗Filed May 15, 2024
Q4 20230.73%7,166SEC filing ↗Filed Feb 14, 2024

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q4 20230.73%7,166$264.86KThe prior quarter is outside the free window. Log in for the comparison.SEC filing ↗
Filed Feb 14, 2024
Q1 20244.05%12,275$499.35KShares increased 71.30%; reported value increased 88.54%, and weight changed +3.32 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 20244.74%36,295$1.89MShares increased 195.68%; reported value increased 278.11%, and weight changed +0.69 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20241.83%11,096$634.14KShares decreased 69.43%; reported value decreased 66.41%, and weight changed -2.91 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 5, 2024
Q4 20242.40%17,596$841.26KShares increased 58.58%; reported value increased 32.66%, and weight changed +0.57 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 7, 2025
Q1 20252.77%33,819$2.16MShares increased 92.20%; reported value increased 156.52%, and weight changed +0.37 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20251.29%55,692$2.90MShares increased 64.68%; reported value increased 34.25%, and weight changed -1.48 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 7, 2025
Q3 20251.62%62,449$4.58MShares increased 12.13%; reported value increased 58.09%, and weight changed +0.33 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 12, 2025
Q4 20251.77%83,030$5.59MShares increased 32.96%; reported value increased 22.01%, and weight changed +0.15 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 10, 2026
Q1 20262.16%95,121$6.15MShares increased 14.56%; reported value increased 10.02%, and weight changed +0.39 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 6, 2026
Q2 20263.19%142,007$11.11MShares increased 49.29%; reported value increased 80.80%, and weight changed +1.03 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 12, 2026
Q3 20262.66%79,799$8.81MShares decreased 43.81%; reported value decreased 20.74%, and weight changed -0.53 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 13, 2026
Future Fund LLC · HALOZYME THERAPEUTICS INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Log in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP / CLI.

MCP  https://api.akkrudata.ai/mcp

akkru_institutional_holdings
{"action":"portfolio","cik":"1911970","quarter":"2026Q3","cusip":"40637H109"}

akkru_institutional_holdings
{"action":"history","cik":"1911970","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP / CLI documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.